Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.

Pio B, Chobanian HR, Guo Y, Josien H, Hagmann WK, Miller M, Trujillo ME, Kirkland M, Kosinski D, Mane J, Pachanski M, Cheewatrakoolpong B, Ashley E, Orr R, Wright MJ, Bugianesi R, Souza S, Zhang X, Di Salvo J, Weinglass AB, Tschirret-Guth R, Samuel K, Chen Q, Shang J, Lamca J, Ehrhart J, Nargund R, Howard AD, Colletti SL.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1842-1848. doi: 10.1016/j.bmcl.2019.04.050. Epub 2019 May 2.

PMID:
31109791
2.

Microbial biotransformation - an important tool for the study of drug metabolism.

Salter R, Beshore DC, Colletti SL, Evans L, Gong Y, Helmy R, Liu Y, Maciolek CM, Martin G, Pajkovic N, Phipps R, Small J, Steele J, de Vries R, Williams H, Martin IJ.

Xenobiotica. 2019 Aug;49(8):877-886. doi: 10.1080/00498254.2018.1512018. Epub 2018 Sep 21.

PMID:
30118378
3.

Profiling and Application of Photoredox C(sp3)-C(sp2) Cross-Coupling in Medicinal Chemistry.

Zhang R, Li G, Wismer M, Vachal P, Colletti SL, Shi ZC.

ACS Med Chem Lett. 2018 May 7;9(7):773-777. doi: 10.1021/acsmedchemlett.8b00183. eCollection 2018 Jul 12.

4.

Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.

Chen HY, Plummer CW, Xiao D, Chobanian HR, DeMong D, Miller M, Trujillo ME, Kirkland M, Kosinski D, Mane J, Pachanski M, Cheewatrakoolpong B, Di Salvo J, Thomas-Fowlkes B, Souza S, Tatosian DA, Chen Q, Hafey MJ, Houle R, Nolting AF, Orr R, Ehrhart J, Weinglass AB, Tschirret-Guth R, Howard AD, Colletti SL.

ACS Med Chem Lett. 2018 Jun 14;9(7):685-690. doi: 10.1021/acsmedchemlett.8b00149. eCollection 2018 Jul 12.

5.

Chemoselective Peptide Modification via Photocatalytic Tryptophan ╬▓-Position Conjugation.

Yu Y, Zhang LK, Buevich AV, Li G, Tang H, Vachal P, Colletti SL, Shi ZC.

J Am Chem Soc. 2018 Jun 6;140(22):6797-6800. doi: 10.1021/jacs.8b03973. Epub 2018 May 23.

PMID:
29762027
6.

Photoredox-catalyzed deuteration and tritiation of pharmaceutical compounds.

Loh YY, Nagao K, Hoover AJ, Hesk D, Rivera NR, Colletti SL, Davies IW, MacMillan DWC.

Science. 2017 Dec 1;358(6367):1182-1187. doi: 10.1126/science.aap9674. Epub 2017 Nov 9.

7.

GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.

Pachanski MJ, Kirkland ME, Kosinski DT, Mane J, Cheewatrakoolpong B, Xue J, Szeto D, Forrest G, Miller C, Bunzel M, Plummer CW, Chobanian HR, Miller MW, Souza S, Thomas-Fowlkes BS, Ogawa AM, Weinglass AB, Di Salvo J, Li X, Feng Y, Tatosian DA, Howard AD, Colletti SL, Trujillo ME.

PLoS One. 2017 Oct 20;12(10):e0186033. doi: 10.1371/journal.pone.0186033. eCollection 2017.

8.

Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40.

Lu J, Byrne N, Wang J, Bricogne G, Brown FK, Chobanian HR, Colletti SL, Di Salvo J, Thomas-Fowlkes B, Guo Y, Hall DL, Hadix J, Hastings NB, Hermes JD, Ho T, Howard AD, Josien H, Kornienko M, Lumb KJ, Miller MW, Patel SB, Pio B, Plummer CW, Sherborne BS, Sheth P, Souza S, Tummala S, Vonrhein C, Webb M, Allen SJ, Johnston JM, Weinglass AB, Sharma S, Soisson SM.

Nat Struct Mol Biol. 2017 Jul;24(7):570-577. doi: 10.1038/nsmb.3417. Epub 2017 Jun 5.

PMID:
28581512
9.

GPR40 reduces food intake and body weight through GLP-1.

Gorski JN, Pachanski MJ, Mane J, Plummer CW, Souza S, Thomas-Fowlkes BS, Ogawa AM, Weinglass AB, Di Salvo J, Cheewatrakoolpong B, Howard AD, Colletti SL, Trujillo ME.

Am J Physiol Endocrinol Metab. 2017 Jul 1;313(1):E37-E47. doi: 10.1152/ajpendo.00435.2016. Epub 2017 Mar 14.

10.

Design and Synthesis of Novel, Selective GPR40 AgoPAMs.

Plummer CW, Clements MJ, Chen H, Rajagopalan M, Josien H, Hagmann WK, Miller M, Trujillo ME, Kirkland M, Kosinski D, Mane J, Pachanski M, Cheewatrakoolpong B, Nolting AF, Orr R, Christensen M, Campeau LC, Wright MJ, Bugianesi R, Souza S, Zhang X, Di Salvo J, Weinglass AB, Tschirret-Guth R, Nargund R, Howard AD, Colletti SL.

ACS Med Chem Lett. 2017 Jan 23;8(2):221-226. doi: 10.1021/acsmedchemlett.6b00443. eCollection 2017 Feb 9.

11.

Systematic chemical modifications of single stranded siRNAs significantly improved CTNNB1 mRNA silencing.

Chang W, Pei Y, Guidry EN, Zewge D, Parish CA, Sherer EC, DiMuzio J, Zhang H, South VJ, Strapps WR, Sepp-Lorenzino L, Colletti SL, Stanton MG.

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4513-4517. doi: 10.1016/j.bmcl.2016.07.064. Epub 2016 Jul 28.

PMID:
27503684
12.

Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates.

Parmar RG, Poslusney M, Busuek M, Williams JM, Garbaccio R, Leander K, Walsh E, Howell B, Sepp-Lorenzino L, Riley S, Patel M, Kemp E, Latham A, Leone A, Soli E, Burke RS, Carr B, Colletti SL, Wang W.

Bioconjug Chem. 2014 May 21;25(5):896-906. doi: 10.1021/bc400527e. Epub 2014 May 5.

PMID:
24742200
13.

Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates.

Barrett SE, Burke RS, Abrams MT, Bason C, Busuek M, Carlini E, Carr BA, Crocker LS, Fan H, Garbaccio RM, Guidry EN, Heo JH, Howell BJ, Kemp EA, Kowtoniuk RA, Latham AH, Leone AM, Lyman M, Parmar RG, Patel M, Pechenov SY, Pei T, Pudvah NT, Raab C, Riley S, Sepp-Lorenzino L, Smith S, Soli ED, Staskiewicz S, Stern M, Truong Q, Vavrek M, Waldman JH, Walsh ES, Williams JM, Young S, Colletti SL.

J Control Release. 2014 Jun 10;183:124-37. doi: 10.1016/j.jconrel.2014.03.028. Epub 2014 Mar 21.

PMID:
24657948
14.

An in vivo evaluation of amphiphilic, biodegradable peptide copolymers as siRNA delivery agents.

Barrett SE, Abrams MT, Burke R, Carr BA, Crocker LS, Garbaccio RM, Howell BJ, Kemp EA, Kowtoniuk RA, Latham AH, Leander KR, Leone AM, Patel M, Pechenov S, Pudvah NT, Riley S, Sepp-Lorenzino L, Walsh ES, Williams JM, Colletti SL.

Int J Pharm. 2014 May 15;466(1-2):58-67. doi: 10.1016/j.ijpharm.2014.03.011. Epub 2014 Mar 5.

PMID:
24607208
15.

Improving the in vivo therapeutic index of siRNA polymer conjugates through increasing pH responsiveness.

Guidry EN, Farand J, Soheili A, Parish CA, Kevin NJ, Pipik B, Calati KB, Ikemoto N, Waldman JH, Latham AH, Howell BJ, Leone A, Garbaccio RM, Barrett SE, Parmar RG, Truong QT, Mao B, Davies IW, Colletti SL, Sepp-Lorenzino L.

Bioconjug Chem. 2014 Feb 19;25(2):296-307. doi: 10.1021/bc400442p. Epub 2014 Jan 10.

PMID:
24409989
16.

Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics.

Parmar RG, Busuek M, Walsh ES, Leander KR, Howell BJ, Sepp-Lorenzino L, Kemp E, Crocker LS, Leone A, Kochansky CJ, Carr BA, Garbaccio RM, Colletti SL, Wang W.

Bioconjug Chem. 2013 Apr 17;24(4):640-7. doi: 10.1021/bc300600a. Epub 2013 Mar 25.

PMID:
23496378
17.

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A.

Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877.

18.

(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.

Boatman PD, Lauring B, Schrader TO, Kasem M, Johnson BR, Skinner P, Jung JK, Xu J, Cherrier MC, Webb PJ, Semple G, Sage CR, Knudsen J, Chen R, Luo WL, Caro L, Cote J, Lai E, Wagner J, Taggart AK, Carballo-Jane E, Hammond M, Colletti SL, Tata JR, Connolly DT, Waters MG, Richman JG.

J Med Chem. 2012 Apr 26;55(8):3644-66. doi: 10.1021/jm2010964. Epub 2012 Apr 9.

PMID:
22435740
19.

Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.

Wu Z, Yang C, Graham TH, Verras A, Chabin RM, Xu S, Tong X, Xie D, Lassman ME, Bhatt UR, Garcia-Calvo MM, Shen Z, Chen Q, Bleasby K, Sinharoy R, Hale JJ, Tata JR, Pinto S, Colletti SL, Shen DM.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1727-30. doi: 10.1016/j.bmcl.2011.12.098. Epub 2012 Jan 8.

PMID:
22290078
20.

Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine.

Wu Z, Yang C, Xiong Y, Feng Z, Lombardo M, Verras A, Chabin RM, Xu S, Tong X, Xie D, Lassman ME, Bhatt UR, Garcia-Calvo MM, Geissler W, Shen Z, Chen Q, Sinharoy R, Hale JJ, Tata JR, Pinto S, Shen DM, Colletti SL.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1774-8. doi: 10.1016/j.bmcl.2011.12.064. Epub 2011 Dec 24.

PMID:
22248857
21.

The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors.

Graham TH, Shen HC, Liu W, Xiong Y, Verras A, Bleasby K, Bhatt UR, Chabin RM, Chen D, Chen Q, Garcia-Calvo M, Geissler WM, He H, Lassman ME, Shen Z, Tong X, Tung EC, Xie D, Xu S, Colletti SL, Tata JR, Hale JJ, Pinto S, Shen DM.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):658-65. doi: 10.1016/j.bmcl.2011.10.060. Epub 2011 Oct 24.

PMID:
22079761
22.

International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B).

Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, IJzerman AP.

Pharmacol Rev. 2011 Jun;63(2):269-90. doi: 10.1124/pr.110.003301. Epub 2011 Mar 31. Review.

PMID:
21454438
23.

Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors.

Shen HC, Ding FX, Zhou C, Xiong Y, Verras A, Chabin RM, Xu S, Tong X, Xie D, Lassman ME, Bhatt UR, Garcia-Calvo MM, Geissler W, Shen Z, Chen D, Sinharoy R, Hale JJ, Tata JR, Pinto S, Shen DM, Colletti SL.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1299-305. doi: 10.1016/j.bmcl.2011.01.090. Epub 2011 Jan 26.

PMID:
21315588
24.

The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties.

Imbriglio JE, DiRocco D, Bodner R, Raghavan S, Chen W, Marley D, Esser C, Holt TG, Wolff MS, Taggart AK, Waters MG, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2011 May 1;21(9):2721-4. doi: 10.1016/j.bmcl.2010.11.116. Epub 2010 Dec 4.

PMID:
21185185
25.

Medicinal chemistry of siRNA delivery.

Stanton MG, Colletti SL.

J Med Chem. 2010 Nov 25;53(22):7887-901. doi: 10.1021/jm1003914. Epub 2010 Aug 31. No abstract available.

PMID:
20806941
26.

GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.

Imbriglio JE, Chang S, Liang R, Raghavan S, Schmidt D, Smenton A, Tria S, Schrader TO, Jung JK, Esser C, Holt TG, Wolff MS, Taggart AK, Cheng K, Carballo-Jane E, Waters MG, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4. doi: 10.1016/j.bmcl.2010.06.041. Epub 2010 Jun 10.

PMID:
20615702
27.

Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.

Ding FX, Shen HC, Wilsie LC, Krsmanovic ML, Taggart AK, Ren N, Cai TQ, Wang J, Tong X, Holt TG, Chen Q, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3372-5. doi: 10.1016/j.bmcl.2010.04.013. Epub 2010 Apr 11.

PMID:
20452209
28.

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.

Shen HC, Ding FX, Raghavan S, Deng Q, Luell S, Forrest MJ, Carballo-Jane E, Wilsie LC, Krsmanovic ML, Taggart AK, Wu KK, Wu TJ, Cheng K, Ren N, Cai TQ, Chen Q, Wang J, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2010 Mar 25;53(6):2666-70. doi: 10.1021/jm100022r.

PMID:
20184326
29.

A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Deng Q, Xu S, Tong X, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Roy S, Zhang B, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. doi: 10.1016/j.bmcl.2009.08.006. Epub 2009 Aug 7.

PMID:
19700315
30.

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Deng Q, Xu S, Chen HS, Tong X, Tong V, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Zhang B, Roy S, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5314-20. doi: 10.1016/j.bmcl.2009.07.138. Epub 2009 Aug 6.

PMID:
19682899
31.

Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.

Shen HC, Ding FX, Wang S, Deng Q, Zhang X, Chen Y, Zhou G, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Tsai C, Stevenson AS, Pai LY, Alonso-Galicia M, Chen X, Soisson SM, Roy S, Zhang B, Tata JR, Berger JP, Colletti SL.

J Med Chem. 2009 Aug 27;52(16):5009-12. doi: 10.1021/jm900725r.

PMID:
19645482
32.

Novel patent publications on high-affinity nicotinic acid receptor agonists.

Shen HC, Colletti SL.

Expert Opin Ther Pat. 2009 Jul;19(7):957-67. doi: 10.1517/13543770902991526. Review.

PMID:
19552512
33.

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Wang S, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Chen X, Zhang B, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3398-404. doi: 10.1016/j.bmcl.2009.05.036. Epub 2009 May 18.

PMID:
19481932
34.

Discovery of the development candidate N-tert-butyl nodulisporamide: a safe and efficacious once monthly oral agent for the control of fleas and ticks on companion animals.

Meinke PT, Colletti SL, Fisher MH, Wyvratt MJ, Shih TL, Ayer MB, Li C, Lim J, Ok D, Salva S, Warmke LM, Zakson M, Michael BF, Demontigny P, Ostlind DA, Fink D, Drag M, Schmatz DM, Shoop WL.

J Med Chem. 2009 Jun 11;52(11):3505-15. doi: 10.1021/jm801334v.

PMID:
19445514
35.

Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.

Shen HC, Ding FX, Deng Q, Wilsie LC, Krsmanovic ML, Taggart AK, Carballo-Jane E, Ren N, Cai TQ, Wu TJ, Wu KK, Cheng K, Chen Q, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2009 Apr 23;52(8):2587-602. doi: 10.1021/jm900151e.

PMID:
19309152
36.

GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a.

Imbriglio JE, Chang S, Liang R, Raghavan S, Schmidt D, Smenton A, Tria S, Schrader TO, Jung JK, Esser C, Taggart AK, Cheng K, Carballo-Jane E, Gerard Waters M, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2121-4. doi: 10.1016/j.bmcl.2009.03.014. Epub 2009 Mar 9.

PMID:
19307116
37.

Synthesis and biological evaluation of platensimycin analogs.

Shen HC, Ding FX, Singh SB, Parthasarathy G, Soisson SM, Ha SN, Chen X, Kodali S, Wang J, Dorso K, Tata JR, Hammond ML, Maccoss M, Colletti SL.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1623-7. doi: 10.1016/j.bmcl.2009.02.006. Epub 2009 Feb 7.

PMID:
19233644
38.

Palladium-catalyzed Suzuki-Miyaura coupling of pyridyl-2-boronic esters with aryl halides using highly active and air-stable phosphine chloride and oxide ligands.

Yang DX, Colletti SL, Wu K, Song M, Li GY, Shen HC.

Org Lett. 2009 Jan 15;11(2):381-4. doi: 10.1021/ol802642g.

PMID:
19072215
39.

Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.

Deng Q, Frie JL, Marley DM, Beresis RT, Ren N, Cai TQ, Taggart AK, Cheng K, Carballo-Jane E, Wang J, Tong X, Waters MG, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2008 Sep 15;18(18):4963-7. doi: 10.1016/j.bmcl.2008.08.030. Epub 2008 Aug 14.

PMID:
18760600
40.

Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A.

Shen HC, Taggart AK, Wilsie LC, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2008 Sep 15;18(18):4948-51. doi: 10.1016/j.bmcl.2008.08.039. Epub 2008 Aug 14.

PMID:
18752940
41.

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.

Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, Cherrier MC, Webb PJ, Tamura SY, Boatman PD, Sage CR, Schrader TO, Chen R, Colletti SL, Tata JR, Waters MG, Cheng K, Taggart AK, Cai TQ, Carballo-Jane E, Behan DP, Connolly DT, Richman JG.

J Med Chem. 2008 Aug 28;51(16):5101-8. doi: 10.1021/jm800258p. Epub 2008 Jul 30.

PMID:
18665582
42.

Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.

Raghavan S, Tria GS, Shen HC, Ding FX, Taggart AK, Ren N, Wilsie LC, Krsmanovic ML, Holt TG, Wolff MS, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3163-7. doi: 10.1016/j.bmcl.2008.04.071. Epub 2008 May 1.

PMID:
18477506
43.

Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A.

Shen HC, Szymonifka MJ, Kharbanda D, Deng Q, Carballo-Jane E, Wu KK, Wu TJ, Cheng K, Ren N, Cai TQ, Taggart AK, Wang J, Tong X, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6723-8. Epub 2007 Oct 18.

PMID:
18029181
44.

Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.

Shen HC, Ding FX, Luell S, Forrest MJ, Carballo-Jane E, Wu KK, Wu TJ, Cheng K, Wilsie LC, Krsmanovic ML, Taggart AK, Ren N, Cai TQ, Deng Q, Chen Q, Wang J, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2007 Dec 13;50(25):6303-6. Epub 2007 Nov 10.

PMID:
17994679
45.

Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.

Carballo-Jane E, Gerckens LS, Luell S, Parlapiano AS, Wolff M, Colletti SL, Tata JR, Taggart AK, Waters MG, Richman JG, McCann ME, Forrest MJ.

J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):308-16. Epub 2007 Jun 23.

PMID:
17643322
46.

Gold(I)-catalyzed regioselective cyclizations of silyl ketene amides and carbamates with alkynes.

Minnihan EC, Colletti SL, Toste FD, Shen HC.

J Org Chem. 2007 Aug 3;72(16):6287-9. Epub 2007 Jul 11.

PMID:
17625890
47.

Agonist lead identification for the high affinity niacin receptor GPR109a.

Gharbaoui T, Skinner PJ, Shin YJ, Averbuj C, Jung JK, Johnson BR, Duong T, Decaire M, Uy J, Cherrier MC, Webb PJ, Tamura SY, Zou N, Rodriguez N, Boatman PD, Sage CR, Lindstrom A, Xu J, Schrader TO, Smith BM, Chen R, Richman JG, Connolly DT, Colletti SL, Tata JR, Semple G.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4914-9. Epub 2007 Jun 10.

PMID:
17588745
48.

Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.

Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti SL, Herath K, Cummings R, Salazar O, González I, Basilio A, Vicente F, Genilloud O, Pelaez F, Jayasuriya H, Young K, Cully DF, Singh SB.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7612-6. Epub 2007 Apr 24.

49.

Alpha-heteroarylation of esters, lactones, amides, and lactams by nucleophilic aromatic substitution.

Shen HC, Ding FX, Colletti SL.

Org Lett. 2006 Mar 30;8(7):1447-50.

PMID:
16562913
50.

Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.

Colletti SL, Frie JL, Dixon EC, Singh SB, Choi BK, Scapin G, Fitzgerald CE, Kumar S, Nichols EA, O'Keefe SJ, O'Neill EA, Porter G, Samuel K, Schmatz DM, Schwartz CD, Shoop WL, Thompson CM, Thompson JE, Wang R, Woods A, Zaller DM, Doherty JB.

J Med Chem. 2003 Jan 30;46(3):349-52.

PMID:
12540232

Supplemental Content

Loading ...
Support Center